PURPOSE OF REVIEW: Understanding the molecular basis underlying testicular germ cell tumors (TGCTs) may help improve patient outcomes, particularly for patients with poorer risk or chemoresistant disease. Here, we review the major contemporary advances in elucidating TGCT genetics by discussing patterns of TGCT inheritance, recent genomic and transcriptomic discoveries in TGCT, and the role of genetics in predicting therapeutic resistance and in guiding treatment. RECENT FINDINGS: In the absence of a major high-penetrance TGCT susceptibility gene, inheritance is likely driven by a complex polygenic model with considerable variation. The most common genomic alterations found in TGCTs include gains in chromosome 12p and mutations in KIT, KRAS, and NRAS, particularly in seminomas. Sensitivity to cisplatin-based chemotherapy likely relies on intact TP53, reciprocal loss of heterozygosity, and high mitochondrial priming. Targetable mutations are uncommon in TGCTs, however, posing a challenge for the development of effective personalized therapies. Consistent with the characteristically low tumor mutational burden, immune checkpoint inhibitors do not appear to be effective for most TGCTs. SUMMARY: Refinements in next-generation sequencing techniques over the last few years have enabled considerable advances in elucidating the genomic, transcriptomic, and epigenetic landscape of TGCTs. Future efforts focused on developing novel treatment modalities are needed.
PURPOSE OF REVIEW: Understanding the molecular basis underlying testicular germ cell tumors (TGCTs) may help improve patient outcomes, particularly for patients with poorer risk or chemoresistant disease. Here, we review the major contemporary advances in elucidating TGCT genetics by discussing patterns of TGCT inheritance, recent genomic and transcriptomic discoveries in TGCT, and the role of genetics in predicting therapeutic resistance and in guiding treatment. RECENT FINDINGS: In the absence of a major high-penetrance TGCT susceptibility gene, inheritance is likely driven by a complex polygenic model with considerable variation. The most common genomic alterations found in TGCTs include gains in chromosome 12p and mutations in KIT, KRAS, and NRAS, particularly in seminomas. Sensitivity to cisplatin-based chemotherapy likely relies on intact TP53, reciprocal loss of heterozygosity, and high mitochondrial priming. Targetable mutations are uncommon in TGCTs, however, posing a challenge for the development of effective personalized therapies. Consistent with the characteristically low tumor mutational burden, immune checkpoint inhibitors do not appear to be effective for most TGCTs. SUMMARY: Refinements in next-generation sequencing techniques over the last few years have enabled considerable advances in elucidating the genomic, transcriptomic, and epigenetic landscape of TGCTs. Future efforts focused on developing novel treatment modalities are needed.
Authors: Adam H Hart; Lynne Hartley; Karen Parker; Marilyn Ibrahim; Leendert H J Looijenga; Marija Pauchnik; Chung Wo Chow; Lorraine Robb Journal: Cancer Date: 2005-11-15 Impact factor: 6.860
Authors: Sophie D Fosså; Jinbo Chen; Sara J Schonfeld; Katherine A McGlynn; Mary L McMaster; Mitchell H Gail; Lois B Travis Journal: J Natl Cancer Inst Date: 2005-07-20 Impact factor: 13.506
Authors: Leendert H J Looijenga; Hans Stoop; Hubert P J C de Leeuw; Carlos A de Gouveia Brazao; Ad J M Gillis; Kees E P van Roozendaal; Everardus J J van Zoelen; Rob F A Weber; Katja P Wolffenbuttel; Herman van Dekken; Friedemann Honecker; Carsten Bokemeyer; Elizabeth J Perlman; Dominik T Schneider; Juha Kononen; Guido Sauter; J Wolter Oosterhuis Journal: Cancer Res Date: 2003-05-01 Impact factor: 12.701
Authors: S Bamford; E Dawson; S Forbes; J Clements; R Pettett; A Dogan; A Flanagan; J Teague; P A Futreal; M R Stratton; R Wooster Journal: Br J Cancer Date: 2004-07-19 Impact factor: 7.640